Pulse Biosciences, Inc. (PLSE)

Market Cap	3.48B +242.3%
Revenue (ttm)	1.19M
Net Income	-80.06M
EPS	-1.18
Shares Out	71.32M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	515,419
Open	53.68
Previous Close	53.24
Day's Range	52.75 - 54.75
52-Week Range	12.56 - 55.37
Beta	1.63
Analysts	Strong Buy
Price Target	45.25 (-7.26%)
Earnings Date	Aug 6, 2026

About PLSE

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled conso...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: May 18, 2016
• Employees: 116
• Stock Exchange: NASDAQ
• Ticker Symbol: PLSE
• Website: https://www.pulsebiosciences.com

Analyst Summary

According to 4 analysts, the average rating for PLSE stock is "Strong Buy." The 12-month stock price target is $45.25, which is a decrease of -7.26% from the latest price.

Price Target

$45.25

(-7.26% downside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 9, 2026

Data Sources Report a data error